Vasculopathy in Sjogren's syndrome

被引:7
作者
Feist, E. [1 ]
Hermann, K. -G. A. [2 ]
Dankof, A. [3 ]
机构
[1] Charite, Klin Rheumatol & Klin Immunol, D-10117 Berlin, Germany
[2] Charite, Inst Radiol, D-13353 Berlin, Germany
[3] Charite, Inst Pathol, D-13353 Berlin, Germany
来源
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2009年 / 68卷 / 04期
关键词
Sjogren's syndrome; Vasculitis; Vasculopathy; Extraglandular manifestation; SALIVARY-GLAND BIOPSY; CLINICAL CHARACTERISTICS; CLASSIFICATION; DISEASE; VASCULITIS; MORTALITY; EXPRESSION; RITUXIMAB; LYMPHOMA; COHORT;
D O I
10.1007/s00393-008-0400-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sjogren's syndrome is a systemic autoimmune disease with a predominant involvement of exocrine glands leading to sicca symptoms. Extraglandular involvement occurs in about 40% of patients with skin, musculoskeletal, neurological and organ manifestations. Systemic vasculitic manifestations of Sjogren's syndrome can be assumed in approximately 5%-10% of patients. Leukocytoclastic or cryoglobulinemic vasculitis represent classic vasculitic manifestations of Sjogren's syndrome. In the pathogenesis of vasculitis, B-cell-driven autoimmune processes play a major role by producing autoantibodies against the Ro/SS-A and La/SS-B antigens and cryoglobulins. In patients with Sjogren's syndrome, manifestation of vasculitis, non-Hodgkin's lymphoma and glomerulonephritis, as well as positive cryoglobulins and decreased levels of complement factors, are considered negative prognostic markers. Various immunosuppressive strategies, usually in co-medication with glucocorticoids, are used for the treatment of vasculitis in Sjogren's syndrome. For refractory and severe manifestations, a B-cell-targeted therapy with Rituximab should be also considered.
引用
收藏
页码:305 / 311
页数:7
相关论文
共 31 条
[1]   SJOGRENS SYNDROME - ASSOCIATION OF ANTI-RO(SS-A) ANTIBODIES WITH VASCULITIS, HEMATOLOGIC ABNORMALITIES, AND SEROLOGIC HYPERREACTIVITY [J].
ALEXANDER, EL ;
ARNETT, FC ;
PROVOST, TT ;
STEVENS, MB .
ANNALS OF INTERNAL MEDICINE, 1983, 98 (02) :155-159
[2]   NEUROLOGIC COMPLICATIONS OF PRIMARY SJOGRENS SYNDROME [J].
ALEXANDER, EL ;
PROVOST, TT ;
STEVENS, MB ;
ALEXANDER, GE .
MEDICINE, 1982, 61 (04) :247-257
[3]  
ANDONOPOULOS AP, 1990, BRIT J RHEUMATOL, V29, P21
[4]   Expression of selectins (CD62 E,L,P) and cellular adhesion molecules in primary Sjogren's syndrome: Questions to immunoregulation [J].
Aziz, KE ;
McCluskey, PJ ;
Wakefield, D .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 80 (01) :55-66
[5]   Predicting adverse outcomes in primary Sjogren's syndrome:: identification of prognostic factors [J].
Brito-Zeron, P. ;
Ramos-Casals, M. ;
Bove, A. ;
Sentis, J. ;
Font, J. .
RHEUMATOLOGY, 2007, 46 (08) :1359-1362
[6]   LABIAL SALIVARY GLAND BIOPSY IN SJOGRENS DISEASE [J].
CHISHOLM, DM ;
MASON, DK .
JOURNAL OF CLINICAL PATHOLOGY, 1968, 21 (05) :656-&
[7]  
Dankof A, 2006, PATHOLOGE, V27, P416, DOI 10.1007/s00292-006-0869-3
[8]   Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study [J].
Dass, S. ;
Bowman, S. J. ;
Vital, E. M. ;
Ikeda, K. ;
Pease, C. T. ;
Hamburger, J. ;
Richards, A. ;
Rauz, S. ;
Emery, P. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1541-1544
[9]  
FARRIS AD, 2008, ANTILA AUTOIMMUNITY
[10]  
García-Carrasco M, 2002, J RHEUMATOL, V29, P726